← Back to dashboard
Share
1100%
r/wallstreetbets
Potential Type 1 Diabetes Cure
Investor summaryBullish
ELDN announces 100% insulin independence in small T1D study; low cap suggests upside or buyout potential despite limited sample size.
Bull points
- Clinical data showed 100% of participants achieved insulin independence, a significant therapeutic milestone.
- Low market capitalization of $270 million offers high asymmetric return potential if results are replicated.
- Positive clinical outcomes make the company an attractive acquisition target for larger pharmaceutical firms.
Bear points
- The study sample size was extremely small (only 12 patients), limiting statistical significance and generalizability.
- Early-stage biotech investments carry high binary risk pending larger, more rigorous confirmatory trials.
Post body
Eledone Pharmaceuticals (ELDN) just announced this study where 100% of people achieved insulin independence. It was only 12 patients but still the best result possible. Next step is probably a bigger study but could be a very good investment opportunity as the market capitalization is only $270 million. I feel like it has a ton of room to run and could be a buyout target.
Discussion · top comments
No comment snapshot fetched for this post yet.